#BEGIN_DRUGCARD DB01178

# AHFS_Codes:
Not Available

# ATC_Codes:
M03BB02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Myoflex (Paracetamol + Chlormezanone)

# Brand_Names:
Alinam
Banabil-sintyal
Banabin
Banabin-Sintyal
Banabin-syntyal
Bisina
Chlomedinon
Clorilax
Lobak
Mio-Sed
Miorilax
Muskel
Muskel-Trancopal
Myolespen
Phenarol
Rexan
Rilansyl
Rilaquil
Rilasol
Rilassol
Rilax
Rillasol
Supotran
Suprotan
Tanafol
Trancopal
Trancote
Tranrilax
Transanate

# CAS_Registry_Number:
80-77-3

# ChEBI_ID:
3619

# Chemical_Formula:
C11H12ClNO3S

# Chemical_IUPAC_Name:
2-(4-chlorophenyl)-3-methyl-1$l^{6},3-thiazinane-1,1,4-trione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-anxiety Agents
Antipsychotics
Benzodiazepines
Muscle Relaxants, Central

# Drug_Interactions:
Not Available

# Drug_Reference:
10798243	Seeling A, Oelschlager H, Rothley D: [Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone] Pharmazie. 2000 Apr;55(4):293-6.
15897685	Wollina U, Hipler UC, Seeling A, Oelschlager H: Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro. Skin Pharmacol Physiol. 2005 May-Jun;18(3):132-8.
2399514	Gautier V, Vincon G, Demotes-Mainard F, Albin H: [Pharmacokinetics of chlormezanone in healthy volunteers] Therapie. 1990 Jul-Aug;45(4):315-9.
9770210	Oelschlager H, Klinger W, Rothley D, Seeling A, Bockhard H, Hofmann B, Machts H, Riederer H, Rackur H: [Cleavage and biotransformation of the central muscle relaxant chlormezanone] Pharmazie. 1998 Sep;53(9):620-4.

# Drug_Type:
Approved
Small Molecule
Withdrawn

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
2500 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Chlormezanone

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3

# InChI_Key:
InChIKey=WEQAYVWKMWHEJO-UHFFFAOYSA-N

# Indication:
Used in the management of anxiety and in the treatment of muscle spasm.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00268

# LIMS_Drug_ID:
1178

# Mechanism_Of_Action:
Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

# Melting_Point:
116.2 °C

# Molecular_Weight_Avg:
273.736

# Molecular_Weight_Mono:
273.022641652

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448939

# Pharmacology:
Chlormezanone is a non-benzodiazepine muscle relaxant. It was discontinued worldwide in 1996 by its manufacturer due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis).

# Predicted_LogP_Hydrophobicity:
0.84

# Predicted_LogS:
-2.2

# Predicted_Water_Solubility:
1.61e+00 g/l

# Primary_Accession_No:
DB01178

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
2717

# PubChem_Substance_ID:
46505352

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00865

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Chlormethazanone
Chlormethazone
Chlormezanon
Chlormezanone [BAN:INN:JAN]
Chlormezanonum [INN-Latin]
Clormetazanone
Clormetazon
Clormezanona [INN-Spanish]
Clormezanone [DCIT]
Dichloromethazanone
Dichloromezanone
dl-Chlormezanone

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.

# Update_Date:
2013-02-08 16:19:58 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Chlormezanone

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Mitochondrion
mitochondrial membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
TSPO

# Drug_Target_1_GenBank_ID_Gene:
M36035

# Drug_Target_1_GenBank_ID_Protein:
306883

# Drug_Target_1_GeneCard_ID:
TSPO

# Drug_Target_1_Gene_Name:
TSPO

# Drug_Target_1_Gene_Sequence:
>510 bp
ATGGCCCCGCCCTGGGTGCCCGCCATGGGCTTCACGCTGGCGCCCAGCCTGGGGTGCTTC
GTGGGCTCCCGCTTTGTCCACGGCGAGGGTCTCCGCTGGTACGCCGGCCTGCAGAAGCCC
TCGTGGCACCCGCCCCACTGGGTGCTGGGCCCTGTCTGGGGCACGCTCTACTCAGCCATG
GGGTACGGCTCCTACCTGGTCTGGAAAGAGCTGGGAGGCTTCACAGAGAAGGCTGTGGTT
CCCCTGGGCCTCTACACTGGGCAGCTGGCCCTGAACTGGGCATGGCCCCCCATCTTCTTT
GGTGCCCGACAAATGGGCTGGGCCTTGGTGGATCTCCTGCTGGTCAGTGGGGCGGCGGCN
GCCACTACCGTGGCCTGGTACCAGGTGAGCCCGCTGGCCGCCCGCCTGCTCTACCCCTAC
CTGGCCTGGCTGGCCTTCGCGACCACACTCAACTACTGCGTATGGCGGGACAACCATGGC
TGGCATGGGGGACGGCGGCTGCCAGAGTGA

# Drug_Target_1_General_Function:
Signal transduction mechanisms

# Drug_Target_1_General_References:
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
11215759	Kurumaji A, Nomoto H, Yoshikawa T, Okubo Y, Toru M: An association study between two missense variations of the benzodiazepine receptor (peripheral) gene and schizophrenia in a Japanese sample. J Neural Transm. 2000;107(4):491-500.
11304832	Kurumaji A, Nomoto H, Yamada K, Yoshikawa T, Toru M: No association of two missense variations of the benzodiazepine receptor (peripheral) gene and mood disorders in a Japanese sample. Am J Med Genet. 2001 Mar 8;105(2):172-5.
1847678	Riond J, Mattei MG, Kaghad M, Dumont X, Guillemot JC, Le Fur G, Caput D, Ferrara P: Molecular cloning and chromosomal localization of a human peripheral-type benzodiazepine receptor. Eur J Biochem. 1991 Jan 30;195(2):305-11.
7721091	Yakovlev AG, Ruffo M, Jurka J, Krueger KE: Comparison of repetitive elements in the third intron of human and rodent mitochondrial benzodiazepine receptor-encoding genes. Gene. 1995 Apr 3;155(2):201-5.
9915832	Galiegue S, Jbilo O, Combes T, Bribes E, Carayon P, Le Fur G, Casellas P: Cloning and characterization of PRAX-1. A new protein that specifically interacts with the peripheral benzodiazepine receptor. J Biol Chem. 1999 Jan 29;274(5):2938-52.

# Drug_Target_1_HGNC_ID:
HGNC:1158

# Drug_Target_1_HPRD_ID:
15913

# Drug_Target_1_ID:
811

# Drug_Target_1_Locus:
22q13.31

# Drug_Target_1_Molecular_Weight:
18779

# Drug_Target_1_Name:
Translocator protein

# Drug_Target_1_Number_of_Residues:
169

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF03073	TspO_MBR

# Drug_Target_1_Protein_Sequence:
>Peripheral-type benzodiazepine receptor
MAPPWVPAMGFTLAPSLGCFVGSRFVHGEGLRWYAGLQKPSWHPPHWVLGPVWGTLYSAM
GYGSYLVWKELGGFTEKAVVPLGLYTGQLALNWAWPPIFFGARQMGWALVDLLLVSGAAA
ATTVAWYQVSPLAARLLYPYLAWLAFATTLNYCVWRDNHGWHGGRRLPE

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Responsible for the manifestation of peripheral-type benzodiazepine recognition sites and is most likely to comprise binding domains for benzodiazepines and isoquinoline carboxamides. May play a role in the transport of porphyrins and heme

# Drug_Target_1_SwissProt_ID:
P30536

# Drug_Target_1_SwissProt_Name:
TSPOA_HUMAN

# Drug_Target_1_Synonyms:
Mitochondrial benzodiazepine receptor
PBR
PKBS
Peripheral-type benzodiazepine receptor

# Drug_Target_1_Theoretical_pI:
9.33

# Drug_Target_1_Transmembrane_Regions:
6-26
47-67
80-100
106-126
135-155

#END_DRUGCARD DB01178
